LETTERS
1075numbers of patients studied. However, if the numbers of patients from various studies are pooled, as shown by Baer et a1 (2), then there is no difference between slow and fast acetylators in SLE patients and control subjects. This finding, of course, is different from that seen in many patients with drug-related lupus.In one particular study from my laboratory (3), we showed a difference in acetylator phenotype between white SLE patients (71% slow acetylators) and black SLE patients (58% slow acetylators). This result reflects the clinical observations in the US, that drug-related lupus occurs more frequently in white subjects than in black subjects.I agree with Sardas and coworkers' other conclusions, and would point out that more and better data in different population groups and different racial groups are needed.
The pardoner's lines in the Introduction to the Pardoner's Tale contain the nucleus of nine decades of concentrated debate. Aleslake and drynke represent but two of the elements spinning about the core of controversy. Alestake has led numerous commentators to conclude that the Canterbury caravan halted (in or) at a roadside inn and there heard a revealing narrative from one of their fellows. Partial dissenters concede a momentary pause at the pub but contend the pilgrims retook the road before the Pardoner finished his (Prologue or) Tale. Some opposing critics refuse to concede even a momentary respite. Commentary on drynke has gravitated similarly toward three conflicting forces: Some attribute the Pardoner's self-revelation to drunkenness, others see him as loose-tongued but just lightly tipsy, and still others consider him stone sober throughout.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.